Abraxis BioScience — Q2 2010 Earnings Presentation
7 slides from Abraxis BioScience's earnings presentation, Jul 30, 2010
Slide 1: Q2 2010 Conference Call July 29, 2010
Q2 2010 Conference Call July 29, 2010
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information The discussions during this conference call and presentation will include forward-looking statements. All such forward-looking statements exclude the effects of the proposed acquisition of Abraxis BioScience, unless noted. Celgene's actua
Slide 3: Strategically Positioned for Growth
Strategically Positioned for Growth Record Financial Results Agreement to Acquire Abraxis BioScience Clinical Data Flow from ASCO, EHA and IMW MM-015 IFM 2005-02 CALGB 100104 REVLIMID(r) Japan Multiple Myeloma Approval & Launch Advancing More Than 20 Phase III and Pivotal Programs Significant Progre
Slide 4: 2010 Financial Outlook Update
2010 Financial Outlook Update1 REVLIMID(r) global revenue targeting a range of $2.30 to $2.35 billion Total revenue targeting a range of $3.40 to $3.45 billion Non-GAAP diluted earnings per share targeting a range of $2.65 to $2.70 Includes ~ $0.05 dilution from proposed acquisition of Abraxis BioSc
Slide 5: Q2 2010 Business Review
Q2 2010 Business Review Strong Financial Results Global REVLIMID(r) sales up 48% Y/Y and 11% Q/Q to $587 million Global VIDAZA(r) sales increased 43% Y/Y and 10% Q/Q to $132 million Executing Myeloma Filing Strategies Japan approval and reimbursement achieved EMA NDMM filing planned 2H 2010, followe
Slide 6: Abraxis BioScience
Abraxis BioScience ABRAXANE(r) Approved by FDA and EMA for Second-line Use in Metastatic Breast Cancer Clinical Data at ASCO and AACR 1st Line Non-Small Cell Lung Cancer 1st Line Pancreatic Cancer Hart-Scott-Rodino Submission Filed July 14, 2010 Form S-4 Filed July 29, 2010 Closing Expected Q3/Q4 20
Slide 7: Strategically Positioned to Optimize Global Potential
Strategically Positioned to Optimize Global Potential Leveraging Global Operations Global expansion Market share gains Duration gains Product value proposition Advancing More Than 20 Late-stage Pivotal Phase III Trials Maximizing Clinical and Commercial Potential of Deep and Diverse Pipeline Hematol